Enhancement of allogeneic hematopoietic stem cell transplantation

Patent metadata

Field	Value
Publication number	US-9504715-B2
Application number	US-201514686646-A
Country	US
Kind code	B2
Filing date	Apr 14, 2015
Priority date	Jan 10, 2011
Publication date	Nov 29, 2016
Grant date	Nov 29, 2016

Abstract

Methods and compositions are provided to augment the conversion of mixed hematopoietic cell chimerism to complete donor cell chimerism following allogeneic hematopoietic cell transplantation (HCT), where such transplantation may be utilized for treatment of cancer such as leukemia and lymphoma or for other conditions requiring reconstitution of the hematopoietic system, e.g. treatment of anemias, thalassemias, autoimmune conditions, and the like. The present invention improves on conventional DLI by utilizing a composition of substantially purified donor memory CD8 + T cells as DLI following allogeneic HCT, where the cells are administered at a suitable time following transplantation. The methods provide for a more complete donor chimerism, and have the further benefit of killing tumor cells without GVHD. The memory CD8+ T cells may include one or both of central and effector memory T cells, usually both.

First claim

What is claimed is:

1. A method of enhancing allogeneic hematopoietic cell transplantation and anti-tumor activity in a human, the method comprising:
preventing cancer relapse by administering to the human previously treated for the cancer with an allogeneic hematopoietic cell transplantation a dose of at least 1×10 6 and at least 80% pure donor-derived memory CD8 + T cells selected for with an affinity agent specific for CD8, and comprising central and effector memory T cells that are effective to enhance killing of residual cancer cells in the human in the absence of graft versus host disease, wherein the donor-derived memory T cells are selected from CD8 + CD45RA − and/or CD8 + CD45RO + , wherein the memory CD8 + T cells are administered to the human at least two months after the allogeneic hematopoietic cell transplantation and prior to relapse, and wherein the dose of donor-derived memory T cells enhances complete chimerism.

2. The method of claim 1 , wherein the cancer is a lymphoma.

3. The method of claim 1 , wherein the cancer is a leukemia.

4. A method of enhancing allogeneic hematopoietic cell transplantation and anti-tumor activity in a human, the method comprising:
preventing cancer relapse by administering to the human previously treated for the cancer with an allogeneic hematopoietic cell transplantation, a dose of at least 1×10 6 and at least 80% pure, unprimed donor-derived memory T cells selected from CD8 + CD45RA − and/or CD8 + CD45RO + selected for with an affinity agent specific for CD8, and comprising central and effector memory T cells that are effective to enhance killing of residual cancer cells in the absence of graft versus host disease in the human, wherein the memory CD8 + T cells are administered to the human at least two months after the allogeneic hematopoietic cell transplantation, wherein the human is treated with a chemotherapeutic or a radiological agent to substantially ablate the hematopoietic system prior to the administration of the dose of donor-derived memory T cells, and wherein the dose of donor-derived memory T cells enhances complete chimerism.

5. The method of claim 1 or 4 , wherein the donor-derived CD8 + CD45RA − and/or CD8 + CD45RO + memory T cells are collected from the donor of the allogeneic hematopoietic cell transplantation.

6. The method of claim 1 or 4 , wherein the donor-derived CD8 + CD45RA − and/or CD8 + CD45RO + memory T cells are used directly.

7. The method of claim 1 or 4 , wherein the cancer is a hematologic malignancy.

8. The method of claim 1 or 4 , wherein the donor-derived CD8 + CD45RA − and/or CD8 + CD45RO + memory T cells are frozen or maintained ex vivo in an appropriate culture medium.

9. The method of claim 1 or 4 , wherein the human is a pediatric patient.

10. The method of claim 1 or 4 , wherein the dose administered to the human is a dose of at least 1×10 8 and at least 80% pure, unprimed donor-derived CD8 + CD45RA − and/or CD8 + CD45RO + memory T cells.

11. The method of claim 10 , wherein the human is an adult patient.

12. The method of claim 1 or 4 , wherein the human is at least in partial remission from the cancer.

Assignees

• Univ Leland Stanford Junior

Inventors

• Strober Samuel
• Dutt Suparna
• Lowsky Robert

Classifications

• A61P35/02

  specific for leukemia · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61K2035/124

  the cells being hematopoietic, bone marrow derived or blood cells · CPC title